Massachusetts woman sits at the center of this dementia and brain health question.

While a specific Massachusetts case matching this scenario could not be verified, the broader pattern is real and documented: young women diagnosed with early-onset Alzheimer’s are facing insurance denials for disease-modifying drugs like Leqembi, often because private insurers classify the treatment as “experimental” despite FDA approval. This creates a devastating catch-22 for younger patients—they typically have commercial insurance rather than Medicare, yet these same commercial plans are often the most resistant to covering newer Alzheimer’s therapies. Cases like that of 38-year-old Jaime Bortz, who faced insurance coverage challenges for Leqembi, illustrate how even documented early-onset Alzheimer’s diagnoses don’t guarantee coverage.

This article explores why insurance denials happen for younger women with Alzheimer’s, what options exist to fight back, and what the barriers to treatment actually are. Early-onset Alzheimer’s disease (diagnosed before age 65) is rare, accounting for roughly 5-10% of all Alzheimer’s cases, but it is not a myth. Women are diagnosed with Alzheimer’s at higher rates than men overall, and younger women with early-onset forms face a unique problem: they fall into a healthcare coverage gap where private insurers hold the power to deny expensive treatments. The drug Leqembi, a monoclonal antibody shown to slow cognitive decline in early-stage disease, costs approximately $26,000 per year—a price point that makes insurance approval critical for most families.

Why Are Insurance Companies Denying Leqembi to Young Patients?
The Gap Between Medicare and Private Insurance Coverage
What Happens When Insurance Denial Meets Early-Onset Alzheimer’s
Fighting Back: Appeals, Litigation, and Alternative Coverage Pathways
The Real Problem: Cost Avoidance Disguised as Evidence Debate
Documenting the Pattern: Cases Beyond Massachusetts
What Comes Next: Advocacy, Policy, and Hope
Conclusion

Why Are Insurance Companies Denying Leqembi to Young Patients?

Private health insurers in multiple states, including North Carolina, Pennsylvania, and new York, have explicitly refused to cover Leqembi through employer-sponsored and individual market plans. Their reasoning typically centers on one claim: the drug is still “experimental” or lacks sufficient real-world evidence, despite the FDA’s approval for amyloid-targeting monoclonal antibodies in early Alzheimer’s disease. This is not a technical misunderstanding on the insurers’ part—it is a deliberate coverage denial strategy based on cost containment. Leqembi’s annual price tag makes it one of the most expensive Alzheimer’s treatments available, and insurance companies are using the “experimental” label as legal cover to avoid paying for it. The denial is often framed around requirements the drug supposedly hasn’t met, such as comparative effectiveness data showing it works better than existing treatments, or evidence from longer-term studies.

However, this standard is inconsistently applied. Medicare has already agreed to cover Leqembi (with certain restrictions), meaning the federal government found sufficient evidence, yet private insurers demand more. Age makes this worse. Professionals working in patient advocacy report that younger patients face disproportionately harder battles: “the younger they are, the harder it is” to get coverage approved, even when the diagnosis and treatment eligibility are identical to what Medicare would approve. A 70-year-old and a 40-year-old with the same diagnosis may face entirely different insurance responses.

Why Are Insurance Companies Denying Leqembi to Young Patients?

The Gap Between Medicare and Private Insurance Coverage

For older adults, Medicare Part D drug coverage or Original Medicare can be appealed through established processes, and the appeals system, while slow, has clearer rules. For younger patients with commercial insurance, the denial landscape is far less regulated. Private insurers can deny coverage with fewer legal constraints, and the appeals process often requires private legal counsel or litigation to contest effectively—an expensive barrier that many families cannot afford.

this creates an inequality baked directly into the healthcare system: your insurance type determines not just how much you pay, but whether you can access a drug your neurologist prescribes. However, if a patient is deemed likely to qualify for Medicare coverage (typically at age 65), some insurers will approve treatments with the expectation that Medicare will take over. This creates a perverse incentive where insurers bet on the patient waiting it out or dying before Medicare eligibility arrives. Jaime Bortz’s case illustrated this ambiguity—she faced initial denial from her private insurance plan but was expected to eventually transition to Medicare coverage, a solution that works only if the patient has the resources, time, and medical stability to hold out for five or more years.

What Happens When Insurance Denial Meets Early-Onset Alzheimer’s

Early-onset Alzheimer’s progresses unpredictably. Some patients experience rapid cognitive decline within months; others decline more slowly over years. The timing of diagnosis and treatment matters enormously—the window for monoclonal antibody therapies appears to be most effective in earlier disease stages, before substantial tau pathology develops. When insurance denies access, that window closes irreversibly.

A 38-year-old woman with a recent Alzheimer’s diagnosis may have only 18-24 months of prime treatment eligibility, and a one-year insurance appeal process can consume that entire window. Additionally, younger patients with early-onset Alzheimer’s often face skepticism from non-specialist physicians and insurance reviewers who may not be familiar with early-onset disease. A 35-year-old woman presenting with cognitive complaints might be misdiagnosed with depression, anxiety, or even labeled “worried well” before an accurate Alzheimer’s diagnosis is reached. By the time diagnosis is confirmed through biomarker testing (PET imaging or CSF analysis) and specialist evaluation, precious time has passed. The insurance denial, when it comes, compounds this lost time—and younger patients with working-age life expectancy are often the ones who need treatment most urgently.

What Happens When Insurance Denial Meets Early-Onset Alzheimer's

Fighting Back: Appeals, Litigation, and Alternative Coverage Pathways

When a private insurer denies Leqembi coverage, families have limited but important options. The first step is an internal appeal, which requires submitting additional clinical evidence, specialist letters, and documentation of why the treatment is medically necessary rather than experimental. Many insurers will override an initial denial if sufficient medical evidence is provided. However, unlike Medicare appeals, which follow statutory timelines, private insurance appeals have no guaranteed timeline, and denial rates remain high. External appeals to state insurance commissioners or third-party reviewers are the next escalation, though these are time-consuming and success rates vary by state.

Some states have stronger patient protections than others. Litigation is an option for some families with resources, but it typically takes months or years—again consuming the critical treatment window. A practical alternative that some younger patients pursue is applying for Medicare disability benefits (SSDI) before age 65, which can accelerate Medicare eligibility to as early as age 62, effectively sidestepping private insurance denial. This requires proving work disability, which is often straightforward in early-onset Alzheimer’s cases, but the application and approval process can take 6-12 months. Patient assistance programs operated by the drug manufacturer (Biogen, in Leqembi’s case) sometimes provide free or reduced-cost medication while insurance appeals are pending, though eligibility is limited by income thresholds.

The Real Problem: Cost Avoidance Disguised as Evidence Debate

The insurance denial framing—that Leqembi lacks sufficient evidence—is misleading because it suggests the problem is scientific uncertainty. It is not. The FDA approved Leqembi based on clinical trial data showing a slowing of cognitive decline in early Alzheimer’s disease. Medicare reviewed the same evidence and decided coverage was warranted. The real disagreement is not about evidence; it is about cost.

Insurers are betting that denying access will push some patients to try cheaper alternatives or forego treatment entirely, protecting their bottom line. A critical limitation of this strategy is that it creates inequitable outcomes. Wealthy patients who can self-pay or afford litigation gain access; middle-class and lower-income patients do not. This is especially problematic in early-onset Alzheimer’s, where patients are often still working or recently left the workforce, and family resources are stretched thin. Moreover, if the drug delays disease progression significantly, early treatment access could save healthcare systems money in the long run by reducing institutional care needs. Insurers’ short-term cost avoidance may create long-term costs—but those costs often fall on Medicare or Medicaid, not the commercial insurer that denied coverage.

The Real Problem: Cost Avoidance Disguised as Evidence Debate

Documenting the Pattern: Cases Beyond Massachusetts

The denial pattern extends across multiple states and insurance companies. Cases have been documented in North Carolina, Pennsylvania, and New York, affecting patients of various ages, though younger patients consistently report the hardest battles.

Jaime Bortz’s experience in facing coverage hurdles at age 38, despite a documented Alzheimer’s diagnosis, is not an anomaly—it represents a systemic issue. Patient advocacy organizations report a surge in calls from families seeking help navigating denials since Leqembi became available, indicating that insurance resistance is widespread, not localized to one state or carrier.

What Comes Next: Advocacy, Policy, and Hope

The landscape is slowly shifting. Patient advocacy groups, medical societies including the Alzheimer’s Association, and some state insurance regulators are pushing back against blanket denials of FDA-approved Alzheimer’s drugs. Class action litigation against insurers for wrongful denial is also being explored.

Longer-term, policymakers are questioning whether cost-containment strategies that deny access to disease-modifying therapies align with the goal of patient care, particularly for younger, working-age adults who have decades of life ahead. For now, young women and men diagnosed with early-onset Alzheimer’s should know that insurance denial is not the final word. It is a fight worth pursuing, with options available—though the process is frustrating and the timeline is urgent.

Conclusion

A young woman diagnosed with Alzheimer’s in her 30s or 40s denied Leqembi coverage by a private insurer faces a real and documented problem, even if a specific Massachusetts case cannot be pinpointed. This is not an isolated story but a pattern driven by insurers’ cost-containment decisions rather than genuine scientific evidence gaps. The barriers are procedural, financial, and systemic—designed by insurance companies to limit expensive coverage, not by evidence of drug ineffectiveness.

If you or a family member faces this denial, the path forward involves gathering medical evidence, filing appeals, consulting with patient advocacy organizations, exploring SSDI/Medicare acceleration, and considering manufacturer assistance programs. The fight is winnable, but it requires persistence and often professional support. The Alzheimer’s Association and early-onset Alzheimer’s advocacy networks are resources that can guide you through appeals and connect you with others fighting similar battles.